홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
日本語
English
Русский
中文
Español
Português
Deutsch
한국어
Français
Italiano
Türkçe
CGTX
#3321
Cognition Therapeutics, Inc. Common Stock
1.0
9
-5.22%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-5.22%
월간 변동
-18.66%
6달 변화
-58.87%
년간 변동율
+142.22%
이전 종가
1.1
5
Open
1.0
9
Bid
Ask
Low
1.0
9
High
1.0
9
양
16
마켓
주식
헬스케어
CGTX
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
22.58 M
29.26 M
39 M
61.97 M
—
Valuation ratios
Enterprise value
87.98 M
18.43 M
45.74 M
18.45 M
119.97 M
Price to earnings ratio
-2.02
-2.25
-2.26
-0.82
-4.89
Price to sales ratio
24.56
1 730.8
2 157.65
-142.89
—
Price to cash flow ratio
9.04
2.61
3.64
0.98
4.62
Price to book ratio
0.64
1.2
2.38
1.49
3.1
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
-0.2
-0.42
-0.73
-1.12
-1.08
Return on equity %
-0.23
-0.53
-1.05
-1.81
-2.2
Return on invested capital %
-7 279.36
-4 738.31
-4 705.93
-7 741.22
—
Gross margin %
100
100
100
100
—
Operating margin %
-2 140.57
-155.54 K
-187.87 K
27.67 K
—
EBITDA margin %
—
—
—
—
—
Net margin %
-876.95
-76.42 K
-95.51 K
17.42 K
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
7.5
6.11
3.37
2.65
12.73
Inventory turnover
—
—
—
—
—
Asset turnover
0.02
0
0
-0.01
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.7
-0.78
-0.53
-0.72
-0.54
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
10.54
1.76
1
0.63
1.65
Net current asset value per share
11.36
2.02
1.14
0.74
2.06
Tangible book value per share
9.88
1.7
0.82
0.47
1.32
Working capital per share
9.85
1.69
0.8
0.46
1.3
Book value per share
9.88
1.7
0.82
0.47
1.32
뉴스
コグニション・セラピューティクス、レビー小体型認知症薬についてFDAと会議
Cognition Therapeutics holds FDA meeting on Lewy bodies dementia drug
コグニション社のDLB治療薬、第2相試験で良好な結果を示す
Cognition’s DLB drug shows positive results in phase 2 trial
コグニション・セラピューティクス、拡大アクセスプログラムの登録完了
Cognition Therapeutics completes enrollment in expanded access program
コグニション・セラピューティクス、アルツハイマー病薬の第3相試験計画を発表
Cognition Therapeutics outlines Phase 3 plans for Alzheimer’s drug
Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold (NASDAQ:CGTX)
コグニション・セラピューティクス、アルツハイマー病薬の治験登録完了
Cognition Therapeutics completes enrollment in Alzheimer’s drug trial
Has ANI Pharmaceuticals (ANIP) Outpaced Other Medical Stocks This Year?